Yuto Shiode

438 total citations
8 papers, 342 citations indexed

About

Yuto Shiode is a scholar working on Epidemiology, Molecular Biology and Hepatology. According to data from OpenAlex, Yuto Shiode has authored 8 papers receiving a total of 342 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Epidemiology, 4 papers in Molecular Biology and 3 papers in Hepatology. Recurrent topics in Yuto Shiode's work include Liver Disease Diagnosis and Treatment (3 papers), Autophagy in Disease and Therapy (2 papers) and Endoplasmic Reticulum Stress and Disease (2 papers). Yuto Shiode is often cited by papers focused on Liver Disease Diagnosis and Treatment (3 papers), Autophagy in Disease and Therapy (2 papers) and Endoplasmic Reticulum Stress and Disease (2 papers). Yuto Shiode collaborates with scholars based in Japan, United States and Thailand. Yuto Shiode's co-authors include Tomohide Tatsumi, Ryotaro Sakamori, Tetsuo Takehara, Hayato Hikita, Hidetoshi Eguchi, Sadatsugu Sakane, Satoshi Tanaka, Tasuku Nakabori, Hiroaki Nagano and Keisuke Tabata and has published in prestigious journals such as Hepatology, Cancer Research and Scientific Reports.

In The Last Decade

Yuto Shiode

8 papers receiving 341 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuto Shiode Japan 5 258 114 77 51 44 8 342
Prachi Hote United States 5 232 0.9× 172 1.5× 42 0.5× 43 0.8× 72 1.6× 6 433
Federica Roccio France 5 157 0.6× 153 1.3× 83 1.1× 24 0.5× 23 0.5× 6 326
Takahiro Dohmen Japan 9 155 0.6× 100 0.9× 32 0.4× 55 1.1× 64 1.5× 19 335
Yuta Shimanaka Japan 10 225 0.9× 192 1.7× 140 1.8× 53 1.0× 42 1.0× 16 453
Fredy Z. Saudale Indonesia 3 274 1.1× 141 1.2× 47 0.6× 57 1.1× 68 1.5× 11 422
Leila Valanejad United States 13 151 0.6× 208 1.8× 62 0.8× 114 2.2× 36 0.8× 15 481
Bert Van Den Bossche Belgium 5 266 1.0× 133 1.2× 35 0.5× 93 1.8× 54 1.2× 10 470
Francesca Virginia Bruschi Austria 11 361 1.4× 86 0.8× 132 1.7× 74 1.5× 143 3.3× 13 465
Jin Yoo South Korea 7 171 0.7× 113 1.0× 26 0.3× 31 0.6× 41 0.9× 10 364
Kapil Kampe Switzerland 7 103 0.4× 113 1.0× 55 0.7× 98 1.9× 51 1.2× 9 361

Countries citing papers authored by Yuto Shiode

Since Specialization
Citations

This map shows the geographic impact of Yuto Shiode's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuto Shiode with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuto Shiode more than expected).

Fields of papers citing papers by Yuto Shiode

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuto Shiode. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuto Shiode. The network helps show where Yuto Shiode may publish in the future.

Co-authorship network of co-authors of Yuto Shiode

This figure shows the co-authorship network connecting the top 25 collaborators of Yuto Shiode. A scholar is included among the top collaborators of Yuto Shiode based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuto Shiode. Yuto Shiode is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Shiode, Yuto, Takahiro Kodama, Yu Sato, et al.. (2025). Folate receptor 1 is a stemness trait-associated diagnostic and prognostic marker for hepatocellular carcinoma. Biomarker Research. 13(1). 37–37. 1 indexed citations
3.
Murai, Kazuhiro, Takahiro Kodama, Hayato Hikita, et al.. (2022). Inhibition of nonhomologous end joining‐mediated DNA repair enhances anti‐HBV CRISPR therapy. Hepatology Communications. 6(9). 2474–2487. 9 indexed citations
4.
Mizutani, Naoki, Hayato Hikita, Yoshinobu Saito, et al.. (2021). Gab1 in livers with persistent hepatocyte apoptosis has an antiapoptotic effect and reduces chronic liver injury, fibrosis, and tumorigenesis. American Journal of Physiology-Gastrointestinal and Liver Physiology. 320(6). G958–G968. 6 indexed citations
5.
Shiode, Yuto, Hayato Hikita, Satoshi Tanaka, et al.. (2020). Hepatitis C virus enhances Rubicon expression, leading to autophagy inhibition and intracellular innate immune activation. Scientific Reports. 10(1). 15290–15290. 18 indexed citations
6.
Nozaki, Yasutoshi, Hayato Hikita, Satoshi Tanaka, et al.. (2017). Abstract 4797: Continuous hepatocyte apoptosis accelerates diethylnitrosamine-induced liver tumor development. Cancer Research. 77(13_Supplement). 4797–4797. 2 indexed citations
7.
Tanaka, Satoshi, Hayato Hikita, Tomohide Tatsumi, et al.. (2016). Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice. Hepatology. 64(6). 1994–2014. 287 indexed citations
8.
Kato, Minoru, Masafumi Naito, Mina Kato, et al.. (2013). A case of HCC occurred 5 years and 17 years after sustained virological response of interferon therapy for chronic hepatitis C. Kanzo. 54(7). 491–498. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026